Previous close | 7.00 |
Open | 5.50 |
Bid | 3.00 |
Ask | 7.60 |
Strike | 85.00 |
Expiry date | 2024-06-21 |
Day's range | 5.50 - 5.50 |
Contract range | N/A |
Volume | |
Open interest | 8 |
Bristol Myers (BMY) wins FDA approval for Krazati, in combination with Erbitux, as a targeted treatment option for adult patients with KRASG12C-mutated locally advanced or metastatic colorectal cancer.
Roche (RHHBY) gets exclusive, target-specific rights to Ascidian's RNA exon editing technology for undisclosed neurological targets for an initial payment of $42 million.
Terns Pharmaceuticals, Inc. (TERN) outperforms the industry year to date on encouraging pipeline progress of its oncology candidate.